| Size | Price | Stock |
|---|---|---|
| 1mg | $60 | In-stock |
| 5mg | $250 | In-stock |
| 10mg | $400 | In-stock |
| 25mg | $840 | In-stock |
| 50mg | $1344 | In-stock |
| 100mg | $2083 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-116301 |
| M.Wt: | 523.62 |
| Formula: | C30H37NO7 |
| Purity: | >98 % |
| Solubility: | DMSO : 12.5 mg/mL (ultrasonic;warming;heat to 60°C) |
CAY10502 is a potent, calcium-dependent cytosolic phospholipase A2 α (cPLA2α) inhibitor with an IC50 of 4.3 nM for isolated enzyme. CAY10502 can be used in the research of retinopathy and inflammatory diseases[1][2][3].
In Vitro: CAY10502 inhibits the release of arachidonic acid mediated by cPLA2R stimulanted with A23187 and TPA in human platelets, with IC50s of 0.57 and 0.0009 μM, respectively[1].
CAY10502 (5, 20, 50 nM; 12 hours; müller cells) inhibits normoxic- and hypoxia-induced Prostaglandin E2 (PGE2) and VEGF production[2].
CAY10502 (0.1-100 nM; 24 hours) inhibits the VEGF-induced proliferation of rat retinal microvascular endothelial cells (RRMEC)[2].
CAY10502 (10 μM) inhibits arachidonic acid (AA) release from the phospholipid pools, abrogated extremely low-frequency electromagnetic fields (ELF-EMF; 1 h) induced AA increase and the ELF-EMF inhibitory effect of Cav3.2 channels[3].
In Vivo: CAY10502-injected (2.5, 25, 100 nM; 5 μL) eyes demonstrates a dose-dependent inhibition of retinal neovascularization (NV) in rat oxygen-induced retinopathy (OIR)[2].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information
Your information is safe with us.